Centiva Capital, LP Aerie Pharmaceuticals Inc Transaction History

Centiva Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $318,500 - $761,500	50,000 New	50,000 $757,000
Q1 2022 May 16, 2022	SELL	$5.64 - $9.8 $123,719 - $214,972	-21,936 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $153,990 - $292,406	21,936 New	21,936 $154,000
Q3 2020 Nov 16, 2020	SELL	$10.46 - $14.46 $116,367 - $160,867	-11,125 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$12.0 - $16.13 $10,356 - $13,920	-863 Reduced 7.2%	11,125 $164,000
Q1 2020 May 15, 2020	BUY	$11.84 - $25.52 $141,937 - $305,933	11,988 New	11,988 $162,000
Q4 2019 Feb 14, 2020	SELL	$17.72 - $25.1 $288,906 - $409,230	-16,304 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$18.41 - $28.0 $300,156 - $456,512	16,304 New	16,304 $313,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.